Table 3.
Characteristics stratified by histopathologic class: Baseline and follow-up characteristics
| Characteristic | Focal (n=15) | Crescentic (n=72) | Mixed (n=26) | Sclerotic (n=10) | P Value |
|---|---|---|---|---|---|
| Age, yr | 41±19 | 53±19 | 53±16 | 50±25 | 0.17 |
| Males | 9 (60) | 41 (57) | 10 (39) | 6 (60) | 0.37 |
| Anti-GBM antibodies positivea | 11 (79) | 58 (91) | 17 (71) | 6 (60) | 0.02 |
| Anti-GBM antibodies, ANCA negative | 7 (64) | 37 (67) | 9 (53) | 0 (0) | 0.03 |
| Anti-GBM antibodies, ANCA positive | 4 (36) | 18 (33) | 8 (47) | 5 (100) | |
| ANCA typeb | 0.001 | ||||
| Anti-MPO | 0 (0) | 14 (100) | 7 (87) | 2 (100) | |
| Anti-PR3 | 3 (100) | 0 (0) | 1 (13) | 0 (0) | |
| Lung involvementc | 7 (50) | 26 (37) | 4 (16) | 4 (57) | 0.06 |
| Serum creatinine at presentation, mg/dl | 1.4 (1.0–1.7) | 7.8 (6.4–12.6) | 4.2 (2.6–7.2) | 6.6 (4.5–15.2) | <0.001 |
| Dialysis dependent at presentation | 0 (0) | 51 (71) | 10 (39) | 8 (80) | <0.001 |
| Year of diagnosis | |||||
| 1986–2000 | 3 (20) | 28 (39) | 4 (15) | 6 (60) | <0.01 |
| 2001–2006 | 2 (13) | 26 (36) | 8 (31) | 2 (20) | |
| 2007–2015 | 10 (67) | 18 (25) | 14 (54) | 2 (20) | |
| Duration of follow-up, yr | 4.7±3.7 | 4.9±4.2 | 4.3±3.8 | 3.4±3.6 | 0.72 |
| ESRD at end of follow-up | 1 (7) | 57 (79) | 15 (58) | 9 (90) | <0.001 |
| Transplantation | 0 (0) | 25 (35) | 4 (15) | 3 (30) | 0.01 |
| Death | 2 (13) | 24 (33) | 5 (19) | 3 (30) | 0.32 |
Data are number (%), mean±SD, or median (interquartile range). GBM, glomerular basement membrane; MPO, myeloperoxidase; PR3, proteinase 3.
a
Results from anti-GBM antibody ELISA were available in 112 patients. Results from ANCA ELISA were available in 114 patients. Both tests were performed in 108 patients.
b
Thirty-five patients were anti-GBM antibodies and ANCA positive. Of these, ANCA type (anti-MPO or anti-PR3) was known in 27 patients.
c
Total, n=117 patients.